Gencell Biotechnology
The startup develops an oncolytic herpes simplex virus type 1 (oHSV-1) platform that enhances the immune response while targeting cancer cells. This dual-action approach aims to provide medical professionals with effective treatments for various cancers by leveraging the virus's ability to stimulate both tumor lysis and immune activation.
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops an oncolytic herpes simplex virus type 1 (oHSV-1) platform that enhances the immune response while targeting cancer cells. This dual-action approach aims to provide medical professionals with effective treatments for various cancers by leveraging the virus's ability to stimulate both tumor lysis and immune activation.